Connect with us

Company News

QHSLab announces preliminary unaudited Q1 revenue results

QHSLab, Inc. announced its preliminary unaudited revenue for the first quarter ended March 31, 2024.

Financial highlights:

  • First Quarter Revenues were $488,587, a 38% increase over the $352,799 reported in the first quarter of 2023.
  • First Quarter Gross Profit was $286,157, with a gross profit margin of 59%, compared to $187,342 or a gross profit margin of 53% during the same period last year. This marks a 53% increase in gross profit year-over-year.

Executive commentary: Troy Grogan, President and CEO of QHSLab, Inc., stated, “Our strong preliminary results for the first quarter reflect a pivotal inflection point in our business. We are witnessing the benefits of integrating our core products—QHSLab software, Integrated Service Program (ISP), and AllergiEnd®. This synergy is not only solidifying our market position but is also resonating well with our physician clients and their patients. The growing demand for integrated allergy care and digital health assessments is expected to continue driving our growth.”

Additional information: The results announced today are based on management’s preliminary analysis as of this date. These figures are subject to change following the completion of our standard financial closing procedures. QHSLab anticipates releasing its detailed financial results for the first quarter in the upcoming Quarterly Report on Form 10-Q, which is scheduled to be filed with the Securities and Exchange Commission by May 14, 2024.
MB Bureau

Copyright © 2024 Medical Buyer

error: Content is protected !!